The Netherlands: Forbion raises over €2bn across two newest funds
Leading global life sciences venture capital firm, Forbion, has raised over €2bn (US$2.2bn) across its two newest funds, Forbion Growth Opportunities III and Forbion...
Switzerland: Nuclidium closes CHF79m Series B to advance clinical development of copper-based radiopharmaceutical platform
Nuclidium, a Switzerland-based clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, has closed its Series B financing round, raising CHF79m (US$99m).
The round was...
Switzerland: Roche to acquire 89bio in deal of up to US$3.5bn
Switzerland-headquartered Roche, the world’s largest biotech company and the global leader in in-vitro diagnostics, is acquiring Nasdaq-listed 89bio, a clinical-stage biopharmaceutical company pioneering the...
Switzerland: Healthcare Holding Schweiz acquires stake in Qunique
Healthcare Holding Schweiz, a provider of medical technology services and distribution solutions in Switzerland, has expanded its portfolio and strengthened its expertise in regulatory...
India: Quadria Capital sells partial stake in Nephrocare’s IPO
Quadria Capital, one of Asia’s largest healthcare-focused private equity firms, has sold a partial stake in Nephrocare Health Services, one of the largest dialysis...
Sweden: Changes in Asker’s M&A and ESG management team
Asker a Stockholm-listed provider of medical products and solutions to the European healthcare sector has announced that Lovisa Hedin, currently M&A director, has been...
Switzerland: Partners Group appoints Pete Zippelius as new co-head of Private Equity Health &...
Switzerland listed Partners Group, one of the largest firms in the global private markets industry, has appointed Pete Zippelius as co-head of its Private...
Belgium: Full-Life Technologies raises US$150m to advance clinical stage assets
Full-Life Technologies, a clinical stage radiotherapeutics company with operations in Belgium, Germany, and China, has raised US$150m led by Vivo Capital. Vivo was joined...
UK: Novartis agrees to acquire Myricx Bio for up to US$1.5bn
Swiss multinational pharma, Novartis, has agreed to acquire Myricx Bio, a UK-based biotech company developing a new class of ADCs, using N-myristoyltransferase inhibitor (NMTi)...
UK: Fresh appointments at SV Health Investors
SV Health Investors, a transatlantic venture capital and growth equity firm, is bolstering its senior biotech team with the appointments of Nikola Trbovic as...
Advertisement
